Physician profile
Robert L Roe
NPI 1982710760
$1,373.89
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $349 · 2021: $279 · 2022: $271 · 2023: $50.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $320.53 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $208.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $146.15 | 2019-2020 | |
| Allergan, INC. | $117.22 | 2019-2020 | |
| Novo Nordisk INC | $103.37 | 2019-2022 | |
| Lilly USA, LLC | $85.10 | 2020-2023 | Jardiance |
| Pfizer INC. | $74.58 | 2019-2021 | |
| Abbott Laboratories | $64.49 | 2021-2022 | |
| Amarin Pharma, INC. | $52.10 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $36.58 | 2019 | |
| Glaxosmithkline, LLC. | $24.16 | 2019 | |
| Merck Sharp & Dohme LLC | $23.88 | 2019-2020 | |
| Mylan Specialty L.P. | $20.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.43 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.23 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.52 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.12 | 2019 | |
| Daiichi Sankyo INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.